Roche reports Phase III persevERA breast cancer trial results
Giredestrant shows promise despite missing primary goal
Giredestrant shows promise despite missing primary goal
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated